Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522933 | 0.87 | PIM1 (0.41) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL6520564 | 0.87 | LCK (0.47) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL2519144 | 0.87 | LCK (0.44) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL2521682 | 0.84 | KDM4E (0.48) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL15573656 | 0.81 | LCK (0.41) | LCK | |
| SCHEMBL6525585 | 0.80 | TBK1 (0.44) | LCK | |
| SCHEMBL2518575 | 0.80 | NPC1 (0.38) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL2522570 | 0.80 | LCK (0.38) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL2520688 | 0.80 | USP30 (0.40) | LCKMEN1GAAKMT2AMAPT | |
| SCHEMBL2520080 | 0.80 | KMT2A (0.45) | LCKNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475659-B1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | LCK 64/4885MEN1 2537/4885NPC1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.